RZ Nomics
Rewriting the Future of RNA Therapy
Yongin, South Korea · Founded 2017 · $30.0M raised
- Headquarters
- Yongin
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- rznomics.com
- Total Funding
- $30.0M
- Last Round
- $30.0M Series CJan 2023
- Rounds
- 1
About
Rznomics Inc. (standing for Ribozyme and Omics) is a South Korean biopharmaceutical company founded in 2017 by Professor Seong-Wook Lee at Dankook University, Yongin, South Korea. The company develops RNA-based gene therapies targeting oncology, degenerative diseases, and genetic diseases using its proprietary trans-splicing ribozyme RNA platform. Rznomics has attracted significant partnerships, including a $1.3 billion out-licensing deal with Eli Lilly focused on RNA editing for hearing loss, and is preparing for a Kosdaq IPO.
Summary
RZ Nomics is a Biotech company based in Yongin, South Korea, founded in 2017. It has raised $30.0M in total across 1 round, most recently a $30.0M Series C round in Jan 2023. Investors include Korean Development Bank.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2023
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...